UCB Named a Winner of the 2026 Metro Atlanta Top Workplaces Award Amid $2 Billion Biomanufacturing Expansion
核心洞察
UCB (搜索) has been named a winner of the 2026 Metro Atlanta Top Workplaces Award by Axios (搜索), based solely on confidential employee feedback collected through a third-party survey administered by Energage (搜索).
The recognition comes as UCB (搜索) expands its Georgia footprint through a $2 billion investment in a new biomanufacturing campus in Gwinnett County expected to create more than 330 permanent, highly-skilled jobs.
UCB (搜索) has maintained its U.S. headquarters in metro Atlanta for more than 30 years, employs more than 400 people in Georgia, and plans to establish its first U.S. biomanufacturing campus in the state.
UCB (搜索), a global biopharmaceutical company with its U.S. headquarters in metro Atlanta, has been named a winner of the 2026 Metro Atlanta Top Workplaces Award by Axios (搜索). The recognition, announced August 16, 2026, reflects employee feedback and arrives as UCB deepens its investment in Georgia through a $2 billion commitment to a new biomanufacturing campus expected to create more than 330 jobs.
The Top Workplaces award reinforces UCB (搜索)'s long-term investment in the state, its growing life sciences offering, and its overall culture that attracts, develops, and retains the talent needed to support innovation and a reliable medicine supply for U.S. patients. UCB has maintained its U.S. headquarters in metro Atlanta for more than 30 years and employs more than 400 people in Georgia. Earlier this year, the company announced a $2 billion investment in a new biomanufacturing campus in Gwinnett County expected to create an additional 330+ permanent, highly-skilled jobs and generate an estimated $5 billion in economic impact.
"This recognition is especially meaningful because it reflects the voices and experiences of our people," said Taco van Tiel, Head of UCB (搜索), U.S. "As UCB continues to invest in Georgia, including through our planned U.S. biologics manufacturing site, our ability to attract and support top talent will be central to delivering on our purpose for patients. We are proud to be part of the metro Atlanta community and to continue building a workplace where employees feel empowered to contribute, grow, and make an impact."
Employee Feedback Drives Recognition
Awarded to fewer than 60 organizations with 159-499 employees across metro Atlanta, the recognition is based solely on employee feedback collected through a confidential third-party survey administered by Energage (搜索). UCB (搜索) was previously a recipient of this award in 2021.
"Creating an environment where talented people can do their best work is fundamental to our success at UCB (搜索). This recognition reflects the culture our employees have helped build, one rooted in collaboration, growth, and a shared commitment to improving the lives of people living with severe diseases," said Michele Ehler, Head of U.S. Talent, UCB. "We always strive to create a workplace where employees feel valued and empowered to make a difference, and we remain focused on investing in them as we grow and advance our mission in the years ahead."
UCB (搜索) remains focused on creating an environment where employees can thrive, develop their careers, and contribute to meaningful work. By continuing to invest in its people and culture, UCB is building the foundation needed to support future growth and deliver its commitment to patients.
UCB's Growing Presence in Georgia
Georgia plays a central role in UCB (搜索)'s long-term growth strategy in the United States. In addition to serving as the home of the company's U.S. headquarters, the state will become home to UCB's first U.S. biomanufacturing campus.
UCB (搜索) has maintained a significant U.S. presence for decades, including its U.S. headquarters and eight offices across six communities in California, Georgia, Massachusetts, North Carolina, Washington, and Washington, D.C. With nearly 2,000 U.S. employees focused on research, development, and commercial operations across the country, UCB is adding a U.S. biomanufacturing campus in Georgia, which will create 330+ new, highly skilled jobs. UCB has increased its U.S. workforce by more than 70% since 2017, with over 25% of U.S. employees dedicated to R&D. Over the last decade, UCB has made significant investments in U.S. companies through acquisitions and partnerships and has achieved 15 FDA approvals, advancing innovation, supporting high-quality jobs, and delivering meaningful progress for patients.
UCB (搜索), headquartered in Brussels, Belgium, is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025 and is listed on Euronext Brussels under the symbol UCB.